ID: ALA3398520

Max Phase: Preclinical

Molecular Formula: C21H23F6N5O4

Molecular Weight: 523.43

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(C)C

Standard InChI:  InChI=1S/C21H23F6N5O4/c1-10(2)16(17(33)31-15(18(34)36-3)7-14-8-28-9-29-14)32-19(35)30-13-5-11(20(22,23)24)4-12(6-13)21(25,26)27/h4-6,8-10,15-16H,7H2,1-3H3,(H,28,29)(H,31,33)(H2,30,32,35)/t15-,16-/m0/s1

Standard InChI Key:  YZPUIASTUNJSST-HOTGVXAUSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 523.43

Molecular Weight (Monoisotopic): 523.1654

AlogP: 3.49

#Rotatable Bonds: 8

Polar Surface Area: 125.21

Molecular Species: NEUTRAL

HBA: 5

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 10.29

CX Basic pKa: 6.53

CX LogP: 2.97

CX LogD: 2.92

Aromatic Rings: 2

Heavy Atoms: 36

QED Weighted: 0.31

Np Likeness Score: -0.82

References

1. Daka P, Liu A, Karunaratne C, Csatary E, Williams C, Xiao H, Lin J, Xu Z, Page RC, Wang H..  (2015)  Design, synthesis and evaluation of XZH-5 analogues as STAT3 inhibitors.,  23  (6): [PMID:25698618] [10.1016/j.bmc.2015.01.025]

Source

Source(1):

• Scientific Literature